Back to Newsroom
TrendyVest
TRENDYVEST
The signal. The context. The record.
18 NOV 2026
EQUITY RESEARCH / OPINION

Credo vs. Marvel settles patent dispute

CRDO, MRVL | NASDAQ | Opinion
$123.95
Credo close 17 Nov 2026. Marvell $148.74
The signal: a truce, not a catalystNicholas ThomasBoth report Tue 1 Dec

Fifteen minutes before Nvidia reported on Tuesday, Credo said it had settled its patent dispute with Marvell. Credo's shares were up about 2.5 percent after hours. Marvell's rose half a percent.

I think the market got that about right. The deal ends an argument. It doesn't change what either company earns, and neither stock is down this much because of a patent.

10 of 10
Patent challenges settled
None reached a ruling
-60%
Credo from its 52-week high
$123.95 on Tuesday against $308.67
-55%
Marvell from its 52-week high
$148.74 on Tuesday against $329.88
84%
Credo revenue from four customers
Last quarter. The largest was 33%

01What they were fighting over

The fight was over active electrical cables. These are copper cables with a chip at each end, and the chips let copper carry data further than it otherwise could. AI data centers use them to connect the machines inside a rack.

Credo says it invented them, and it makes the whole thing itself: the chip, the cable and the software. In March 2025 it sued the four companies selling rival cables, which were Amphenol, Molex, TE Connectivity and Volex, and asked the trade commission to block their imports.

Marvell doesn't make cables. It makes the chips inside other companies' cables, and its partners include Amphenol, Molex and TE. In August 2025 it asked the patent office to cancel three of Credo's patents.

Tuesday's agreement settles the two companies' patent rights in these cables and ends Marvell's challenges. The terms are confidential. We don't know who pays whom, or whether anyone pays at all.

02Nobody wanted a ruling

Look at how every one of these fights ended.

Amphenol settled in August 2025, and so did Volex. In February the patent office agreed to hear Marvell's challenge, in a round where it threw out 23 petitions and let 12 through. Within two months Molex and TE had settled as well. Marvell's cases were closed on November 9, about three months before a decision was due.

In all, ten challenges were filed against Credo's patents at the patent office, and all ten ended in a settlement. None of them reached a ruling.

That cuts both ways. Credo's patents were never knocked down, which is what the stock needed. They were also never tested. Credo avoided a decision it might have lost, and its rivals avoided an import ban they might have suffered. Everyone paid for certainty.

03What it means for Credo

It helps, a little.

A legal question that could have gone badly in February is gone, two weeks before Credo reports on December 1. Every company that challenged its patents has now signed an agreement with it. That is an easier story to tell investors than a pending review.

But a license isn't a wall. Amphenol, Molex and TE can go on selling cables with Marvell's chips in them. Credo's edge has to come from the product, and so far it has. Revenue more than doubled last quarter to $479 million, the seventh quarter running of triple-digit growth, at a gross margin of 68 percent.

The stock closed on Tuesday at $123.95. That is 60 percent below its high for the year. Patents didn't do that. The AI selloff did, and so did the customer list. Four customers were 84 percent of revenue last quarter, and the biggest was a third on its own. No settlement fixes that.

If licensed competition ever bites, it will show in that 68 percent margin before it shows anywhere else. That's the number I'd watch on December 1, along with the guide. Credo told investors to expect $525 million to $535 million this quarter.

04What it means for Marvell

Almost nothing, and that's the interesting part.

Cable chips are a small line for Marvell. When it launched one in 2024, it cited a forecast that the whole market for these chips would reach $1 billion a year by 2028. Marvell is aiming for about $18 billion of revenue in its fiscal 2028. The settlement lets its cable customers plan without a lawyer in the room. It doesn't move the numbers.

What moves Marvell's stock is the deal it announced on November 2. It agreed to buy Lumentum in an all-stock deal valued at about $115 billion, and the shares fell nearly 13 percent that day. Lumentum's shareholders will end up with about a third of the combined company. Marvell closed on Tuesday at $148.74, 55 percent below its high.

Read the reason Marvell gave. Its chief executive, Matt Murphy, said the move to optical connections is "creating an opportunity that comes along once in a generation." The company's case for the deal is that copper wiring is running into physical limits.

So in the same month, Marvell made peace over copper cables and gave up a third of itself for the technology it thinks replaces them. That tells you where it believes the money is going.

05The question that matters to both

That is the real question for Credo too. Its cable business depends on copper staying good enough inside the rack for a few more years. If Marvell is right about how fast optics take over, that matters more to Credo than any patent ever did.

Credo isn't standing still. It expects more than $600 million from optical products this fiscal year and bought a photonics company to get there. But cables are still its largest business today.

The tide for both stocks came in fifteen minutes after the settlement. Nvidia guided to $130 billion for the January quarter, and on its call it raised next year's growth forecast to 75 percent. Demand for what these two companies sell depends on that, and it explains Tuesday night's bounce better than the truce does.

06What would change my mind

Two things would make the settlement matter more than I think it does.

The first is money. If Credo's next filings show a jump in licensing income, or Marvell's show a payment, then one side won something, and I'd want to know which.

The second is share. If cables built on Marvell's chips start winning business at Credo's big customers now that the legal risk is gone, the truce will have cost Credo more than it saved. The customer percentages on December 1 are where to look.

07The edge

A settlement closes an argument about the past. Both of these stocks are priced on an argument about the future: how long copper lasts, how few customers Credo depends on, and whether Marvell can digest Lumentum.

Both companies report on December 1. For Credo the truce removes one risk and leaves the big ones. For Marvell it removes a distraction that barely registered. I'd call it a small plus for Credo and nothing for Marvell, and I wouldn't change my view of either stock because of it.

The recordTrendyVest / OPINION

Opinion. Not investment advice, and not a recommendation to buy or sell any security. The terms of the agreement are confidential, and nothing here is a statement about what they contain.

The desk's arithmetic: Credo's Tuesday close of $123.95 is worked back from two feeds, an after-hours price of $127 quoted as 2.46 percent higher and an average analyst target of $270.58 quoted as 118.3 percent above the close. Against a 52-week high of $308.67 that is a fall of 59.8 percent. Marvell's $148.74 against a 52-week high of $329.88 (one feed) is a fall of 54.9 percent. The patent office's decision to hear Marvell's challenge is dated February 3, 2026, and a final decision is normally due within a year. Lumentum's shareholders are to own about 33 percent of the combined company and Marvell's about 67 percent.

More from the Newsroom